The Know AML website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and Know AML cannot guarantee the accuracy of translated content. Know AML and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The myeloMATCH clinical trials: Improving personalized treatment in AML
July 15, 2025
Know AML was pleased to speak with Harry Erba, Professor of Medicine and Director of the Leukemia Program at Duke University in Durham, North Carolina, US. We asked the following questions:
- What sets the myeloMATCH trials apart from previous clinical trials in AML and MDS, and how could it help improve personalized treatment on a global scale?
- Why is the speed of genetic testing so critical in the myeloMATCH trial, and how quickly can patients typically receive results?
Erba explains that the myeloMATCH program is a shared effort to develop new drug options for people with AML, by leukemia experts from hundreds of locations across the US and Canada. Since AML can be caused by a range of different genetic mutations which take place in the bone marrow, various drugs are being investigated that can target these specific mutations. The myeloMATCH program includes multiple clinical trials testing these drugs, to help develop the most appropriate treatments, personalized to each individual patient.
Erba also discusses the importance of rapidly identifying a patient’s specific genetic mutations, to help identify the optimal treatment for them as soon as possible after diagnosis. He highlights the value of the myeloMATCH program in helping to speed up this process – genetic testing results typically take up to 14 days to be processed, while patients in a myeloMATCH clinical trial may receive results within 72 hours.
